Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

clindamycin phosphate

×

Overview

What is ClindaMax Lotion?

ClindaMax Lotion (clindamycin phosphate topical suspension USP 1%) contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per milliliter.

Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.

The topical lotion contains cetostearyl alcohol (2.5%), glycerin, glyceryl stearate SE (with potassium monostearate), isostearyl alcohol (2.5%), methylparaben (0.3%), sodium lauroyl sarcosinate, stearic acid and purified water.

The structural formula is represented below:

The chemical name for clindamycin phosphate is Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl--4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L--α–D--octopyranoside 2-(dihydrogen phosphate).



What does ClindaMax Lotion look like?



What are the available doses of ClindaMax Lotion?

Sorry No records found.

What should I talk to my health care provider before I take ClindaMax Lotion?

Sorry No records found

How should I use ClindaMax Lotion?

ClindaMax Lotion (clindamycin phosphate topical suspension USP 1%) is indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (See and .)

Apply a thin film of ClindaMax® Lotion (clindamycin phosphate topical suspension USP 1%) twice daily to affected area.

Shake well immediately before using.

Keep in container and keep tightly closed.


What interacts with ClindaMax Lotion?

Sorry No Records found


What are the warnings of ClindaMax Lotion?

Sorry No Records found


What are the precautions of ClindaMax Lotion?

Sorry No Records found


What are the side effects of ClindaMax Lotion?

Sorry No records found


What should I look out for while using ClindaMax Lotion?

ClindaMax Lotion (clindamycin phosphate topical suspension USP 1%) is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.

Orally and parenterally administered clindamycin has been associated with severe colitis which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.

Studies indicate a toxin(s) produced by clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Endoscopic examination may reveal pseudomembranous colitis.

Stool culture for

Clostridium difficile

and stool assay for

C. difficile

toxin may be helpful diagnostically.

When significant diarrhea occurs, the drug should be discontinued. Large bowel endoscopy should be considered to establish a definitive diagnosis in cases of severe diarrhea.

Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen the condition. Vancomycin has been found to be effective in the treatment of antibiotic-associated pseudomembranous colitis produced by

Clostridium difficile

. The usual adult dosage is 500 mg to 2 grams of vancomycin orally per day in three to four divided doses administered for 7 to 10 days.

 Cholestyramine or colestipol resins bind vancomycin

in vitro

. If both a resin and vancomycin are to be administered concurrently, it may be advisable to separate the time of administration of each drug.

Diarrhea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of oral and parenteral therapy with clindamycin.


What might happen if I take too much ClindaMax Lotion?

Topically applied ClindaMax® Lotion (clindamycin phosphate topical suspension USP 1%) can be absorbed in sufficient amounts to produce systemic effects. (See .)


How should I store and handle ClindaMax Lotion?

Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP] .ClindaMax® Lotion (clindamycin phosphate topical suspension USP 1%) containing clindamycin phosphate equivalent to 10 mg clindamycin per mL, is supplied as follows: Store at 20°-25°C (68°-77°F). [See USP Controlled Room Temperature]. PharmaDerm® A division of Nycomed US Inc., Melville, NY 11747www.pharmaderm.com I8391C/IF8391C#43R10/08 ClindaMax® Lotion (clindamycin phosphate topical suspension USP 1%) containing clindamycin phosphate equivalent to 10 mg clindamycin per mL, is supplied as follows: Store at 20°-25°C (68°-77°F). [See USP Controlled Room Temperature]. PharmaDerm® A division of Nycomed US Inc., Melville, NY 11747www.pharmaderm.com I8391C/IF8391C#43R10/08 ClindaMax® Lotion (clindamycin phosphate topical suspension USP 1%) containing clindamycin phosphate equivalent to 10 mg clindamycin per mL, is supplied as follows: Store at 20°-25°C (68°-77°F). [See USP Controlled Room Temperature]. PharmaDerm® A division of Nycomed US Inc., Melville, NY 11747www.pharmaderm.com I8391C/IF8391C#43R10/08 ClindaMax® Lotion (clindamycin phosphate topical suspension USP 1%) containing clindamycin phosphate equivalent to 10 mg clindamycin per mL, is supplied as follows: Store at 20°-25°C (68°-77°F). [See USP Controlled Room Temperature]. PharmaDerm® A division of Nycomed US Inc., Melville, NY 11747www.pharmaderm.com I8391C/IF8391C#43R10/08


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Although clindamycin phosphate is inactive , rapid hydrolysis converts this compound to the antibacterially active clindamycin.         Cross resistance has been demonstrated between clindamycin and lincomycin.         Antagonism has been demonstrated between clindamycin and erythromycin.         Following multiple topical applications of clindamycin phosphate at a concentration equivalent to 10 mg clindamycin per mL in an isopropyl alcohol and water solution, very low levels of clindamycin are present in the serum (0-3 ng/mL) and less than 0.2% of the dose is recovered in urine as clindamycin.

Clindamycin activity has been demonstrated in comedones from acne patients. The mean concentration of antibiotic activity in extracted comedones after application of Clindamycin Phosphate Topical Solution for 4 weeks was 597 mcg/g of comedonal material (range 0-1490). Clindamycin inhibits all cultures tested (MICs 0.4 mcg/mL). Free fatty acids on the skin surface have been decreased from approximately 14% to 2% following application of clindamycin.

Non-Clinical Toxicology
ClindaMax Lotion (clindamycin phosphate topical suspension USP 1%) is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.

Orally and parenterally administered clindamycin has been associated with severe colitis which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.

Studies indicate a toxin(s) produced by clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Endoscopic examination may reveal pseudomembranous colitis.

Stool culture for

Clostridium difficile

and stool assay for

C. difficile

toxin may be helpful diagnostically.

When significant diarrhea occurs, the drug should be discontinued. Large bowel endoscopy should be considered to establish a definitive diagnosis in cases of severe diarrhea.

Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen the condition. Vancomycin has been found to be effective in the treatment of antibiotic-associated pseudomembranous colitis produced by

Clostridium difficile

. The usual adult dosage is 500 mg to 2 grams of vancomycin orally per day in three to four divided doses administered for 7 to 10 days.

 Cholestyramine or colestipol resins bind vancomycin

in vitro

. If both a resin and vancomycin are to be administered concurrently, it may be advisable to separate the time of administration of each drug.

Diarrhea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of oral and parenteral therapy with clindamycin.

Drug Interactions:

General

®

In 18 clinical studies of various formulations of topical clindamycin phosphate using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below].

Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally.

Cases of diarrhea, bloody diarrhea and colitis (including pseudomembranous colitis) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see ).

Abdominal pain and gastrointestinal disturbances as well as gram-negative folliculitis have also been reported in association with the use of topical formulations of clindamycin.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).